Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Prostate cancer resistance to androgen deprivation therapy (ADT) is a significant clinical challenge.
• The histone demethylase KDM5D (lysine-specific demethylase 5D) plays a role in ADT resistance.
• Downstream molecular mechanisms driving KDM5D's effect on ADT resistance require elucidation.

Purpose of the Study:

• To identify downstream effectors of KDM5D in prostate cancer.
• To investigate the role of MYBL2 as a downstream driver of KDM5D-mediated ADT resistance.
• To correlate MYBL2 expression with clinical outcomes in prostate cancer patients.

Main Methods:

• Chromatin immunoprecipitation sequencing (ChIP-seq) to identify MYBL2-binding sites in LNCaP cells with altered KDM5D expression.
• In vitro assays involving MYBL2 and KDM5D silencing/overexpression in prostate cancer cell lines (LNCaP, LAPC4).
• Assessment of cellular proliferation, apoptosis, cell cycle, and sensitivity to ADT and taxanes.
• Analysis of MYBL2 mRNA expression and clinical outcomes in patient cohorts.

Main Results:

• Silencing KDM5D increased histone H3 lysine K4 (H3K4) trimethylation and upregulated MYBL2 expression.
• MYBL2 expression was negatively correlated with KDM5D in some clinical samples.
• Higher MYBL2 expression correlated with increased relapse rates in localized prostate cancer and poorer survival in metastatic disease.
• Lower MYBL2 levels sensitized prostate cancer cells to ADT and taxanes (docetaxel, cabazitaxel).

Conclusions:

• The transcription factor MYBL2 is a key downstream mediator of KDM5D's role in prostate cancer.
• MYBL2 influences sensitivity to androgen deprivation and taxane therapies in hormone-sensitive prostate cancer.
• Lower MYBL2 expression is associated with improved clinical outcomes in men with hormone-sensitive prostate cancer, suggesting therapeutic potential.